The null hypothesis is that there is a difference in the the relative rate and extent of
absorption into the systemic circulation of Triomune and brand-name
Stavudine/Lamivudine/Nevirapine in HIV-infected Africans and the alternative hypothesis is
that there is no difference in the the relative rate and extent of absorption into the
systemic circulation of Triomune and brand-name Stavudine/Lamivudine/Nevirapine in
HIV-infected Africans. This is a non-inferiority study.
Phase:
Phase 4
Details
Lead Sponsor:
Makerere University
Collaborator:
University of California, San Francisco
Treatments:
Lamivudine Nevirapine Stavudine Stavudine, lamivudine, nevirapine drug combination